{"filings":[{"id":482799,"accession_number":"0001493152-26-024082","cik":1962011,"company_name":"Kairos Pharma, LTD.","ticker":"KAPA","form_type":"8-K","filed_at":"2026-05-18T12:31:29+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kairos Pharma issues investor presentation for LD Micro Invitational; no material new data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company issued investor presentation for presentation at LD Micro Invitational on May 18-19, 2026.","CEO John Yu will present update on clinical program and partnering activities.","No specific financial results, milestones, or clinical data endpoints provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":11118834.513341067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111341,"accession_number":"0001493152-26-008435","cik":1962011,"company_name":"Kairos Pharma, LTD.","ticker":"KAPA","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Kairos Pharma acquires exclusive worldwide rights to CL-273 from Celyn Therapeutics","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 100% worldwide rights to CL-273, a pan-EGFR inhibitor for EGFR-mutant NSCLC, from Celyn Therapeutics (backed by OrbiMed and Torrey Pines).","Consideration includes 16.5% of Kairos shares on fully diluted basis, $15M milestone upon FDA submission, and 2% royalty on U.S. net revenues.","CL-273 targets $16.2 billion lung cancer market; addresses resistance to existing EGFR TKIs.","Binding term sheet signed March 2, 2026; closing subject to shareholder and NYSE American approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":11118834.513341067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111340,"accession_number":"0001493152-26-008116","cik":1962011,"company_name":"Kairos Pharma, LTD.","ticker":"KAPA","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kairos Pharma signs term sheet to acquire two lung cancer assets from Celyn Therapeutics","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Worldwide rights to CL-273 (pre-IND pan-EGFR inhibitor) and CL-741 (Phase 1-ready c-MET inhibitor) for NSCLC.","No financial terms or expected close date disclosed in press release or filing.","CL-273 is wild-type-sparing with 4-5x wider safety margin; CL-741 targets MET-amplification resistance.","Celyn backed by OrbiMed and Torrey Pines Investment; Kairos plans to use Cedars-Sinai clinical network.","Acquisition aims to address EGFR-mutant and c-MET-driven lung cancer resistance mechanisms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":11118834.513341067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127945,"accession_number":"0001493152-25-018145","cik":1962011,"company_name":"Kairos Pharma, LTD.","ticker":"KAPA","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Kairos Pharma grants $950K RSUs to executives; $227.5K cash bonuses for FY2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total RSU grant value $950K at $1.31/share, vesting Oct 8, 2026 with change-of-control acceleration.","CEO John S. Yu receives 190,840 RSUs ($250K) and $87.5K cash bonus for FY2024.","CSO Neil Bhomick gets 171,756 RSUs ($225K) and $50K cash bonus.","CFO Doug Samuelson gets 152,672 RSUs ($200K) and $50K bonus; VP R&D Ramachandran Murali also gets 152,672 RSUs ($200K) and $40K.","Independent directors Hyun Bae, Hansoo Keyoung, Rahul Singhvi each receive 19,084 RSUs worth $25K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":11118834.513341067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127944,"accession_number":"0001493152-25-017208","cik":1962011,"company_name":"Kairos Pharma, LTD.","ticker":"KAPA","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Kairos Pharma to Present Phase 2 Prostate Cancer Data at ESMO 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On October 7, 2025, Kairos issued press release announcing ESMO Congress presentation in Berlin from October 17-21.","Presentation covers interim analysis of Phase 2 trial evaluating ENV105 (carotuximab) plus apalutamide in mCRPC.","Trial enrolling 100 men at Cedars-Sinai, City of Hope, and Huntsman Cancer Institute.","On October 1, 2025, Kairos Board approved novation agreements with Cedars-Sinai and Tracon to transfer patent licenses from Enviro to Kairos.","Transferred patents include exclusive licenses for mitochondrial DNA depletion and endoglin antagonism therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11118834.513341067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144726,"accession_number":"0001493152-25-013975","cik":1962011,"company_name":"Kairos Pharma, LTD.","ticker":"KAPA","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kairos Pharma reports positive Phase 2 interim efficacy for ENV105 in mCRPC; median PFS >13 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median PFS >13 months in 8 evaluable patients with mCRPC who failed prior hormone therapy.","5 of 8 patients continuing without progression; 7 of 9 showed PSA decrease from baseline.","Trial powered for 45% PFS improvement; actual PFS far exceeded CARD trial benchmark of 3.7-6.7 months.","No Grade 3/4 toxicities observed; ENV105 well tolerated with standard supportive care.","Phase 2 trial enrolling at Cedars-Sinai, City of Hope, Huntsman Cancer Center; KOL event held Sept 18."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":11118834.513341067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144725,"accession_number":"0001493152-25-013040","cik":1962011,"company_name":"Kairos Pharma, LTD.","ticker":"KAPA","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kairos Pharma to host KOL event Sept 18 for ENV105 Phase 2 interim efficacy data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Virtual KOL event on Sept 18, 2025, at 5 p.m. ET to discuss interim efficacy results from ENV105 Phase 2 trial in advanced prostate cancer.","ENV105 is a first-in-class CD105 antagonist; interim safety analysis (July 2025) showed well-tolerated with no dose-limiting toxicities or Grade 3/4 events.","Speakers include principal investigators Drs. Bhowmick, Swami, Lee, and Posadas.","ENV105 targets CD105-driven drug resistance in castration-resistant prostate cancer; trial combines ENV105 with apalutamide."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11118834.513341067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144724,"accession_number":"0001641172-25-026316","cik":1962011,"company_name":"Kairos Pharma, LTD.","ticker":"KAPA","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kairos Pharma to present initial Phase 1 data for ENV105 in NSCLC at World Lung Cancer Conference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Karen Reckamp to present combination of ENV105 (carotuximab) with osimertinib for advanced EGFR-mutated NSCLC.","Presentation at World Lung Cancer Conference in Barcelona, Spain, September 6-9, 2025.","Primary objective of open-label Phase 1 trial is to evaluate safety and tolerability of the combination.","ENV105 targets CD105 to reverse drug resistance; also in Phase 2 for castrate-resistant prostate cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":11118834.513341067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144723,"accession_number":"0001641172-25-019645","cik":1962011,"company_name":"Kairos Pharma, LTD.","ticker":"KAPA","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kairos Pharma reports positive safety results from Phase 2 ENV-105 trial in mCRPC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No dose-limiting toxicities or unexpected adverse events in first 10 patients.","No Grade 3 or 4 toxicities observed; side effects manageable with standard care.","Phase 2 trial to enroll 100 patients; interim efficacy data expected September 2025.","Company plans to discuss potential pivotal Phase 3 study design with regulators."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":11118834.513341067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163126,"accession_number":"0001641172-25-014905","cik":1962011,"company_name":"Kairos Pharma, LTD.","ticker":"KAPA","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["1.01","5.07","9.01"],"status":"ready","headline":"Kairos Pharma shareholders approve dilutive stock issuance, elect directors, enter IR pact","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered one-year IR services agreement with Barretto Pacific Corp for $170,000 fee.","Shareholders elected all four director nominees (Yu, Bae, Keyoung, Sighvi).","Ratified Weinberg & Company as independent auditor for FY2025.","Approved issuance of >20% common stock at price below NYSE American minimum price.","Advisory votes approved executive compensation and 1-year frequency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":11118834.513341067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163125,"accession_number":"0001641172-25-013368","cik":1962011,"company_name":"Kairos Pharma, LTD.","ticker":"KAPA","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kairos Pharma presents KROS101 preclinical data at ASCO; shows superiority over TRX518","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KROS101 is a small molecule GITR ligand agonist with dual mechanisms: promotes T effector proliferation and reduces T reg suppression.","Preclinical study showed KROS101 enhanced T cell cytotoxicity and cytokine production, boosting tumor cell killing.","KROS101 was superior to anti-GITR antibody TRX518 in T cell tumor infiltration, T reg reduction, and preventing T cell exhaustion.","CEO Dr. John Yu presented findings at ASCO 2025 (May 30-June 3) and expressed strong support for continued study of KROS101."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11118834.513341067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163124,"accession_number":"0001641172-25-006504","cik":1962011,"company_name":"Kairos Pharma, LTD.","ticker":"KAPA","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Kairos Pharma replaces auditor Marcum with Weinberg; 2023 report had going concern","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee dismissed Marcum LLP and appointed Weinberg & Company effective April 23, 2025.","Marcum's 2023 audit report included a going concern uncertainty; 2024 report had no such modification.","No disagreements on accounting principles or audit scope occurred during Marcum's tenure.","Material weaknesses in internal control over financial reporting were disclosed for 2024 and 2023.","Marcum provided a letter agreeing with the statements in this 8-K filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":11118834.513341067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163123,"accession_number":"0001641172-25-005946","cik":1962011,"company_name":"Kairos Pharma, LTD.","ticker":"KAPA","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kairos Pharma CEO letter updates ENV105 trials, DoD grant, and analyst coverage","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["ENV105 in Phase 2 prostate cancer and Phase 1 lung cancer trials; interim efficacy data expected end of Q2 2025.","CSO lab received $876k DoD grant for biomarker study; trial sites expanded to University of Utah and City of Hope.","Developing KROS101 GITR ligand agonist; data presented at AACR, SITC, and upcoming ASCO.","Non-dilutive government grants received; robust IP portfolio; analyst coverage from EF Hutton, Maxim, HC Wainwright, and others.","Financially strong due to recent private placement and non-dilutive funding; attending D. Boral and HC Wainwright conferences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":11118834.513341067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181040,"accession_number":"0001493152-25-010977","cik":1962011,"company_name":"Kairos Pharma, LTD.","ticker":"KAPA","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kairos Pharma publishes study showing CD105 blockade restores osimertinib sensitivity in NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study in Drug Resistance Updates shows CD105 upregulation drives resistance to EGFR-targeted therapy osimertinib.","Preclinical models: ENV105 (carotuximab) combined with osimertinib restored drug sensitivity via metabolic reprogramming.","CEO states CD105 is a central resistance mechanism across prostate, breast, colon, and lung cancers.","ENV105 currently in Phase 2 for castrate-resistant prostate cancer and Phase 1 for lung cancer.","Global NSCLC treatment market projected to reach $45B by 2030; drug resistance remains a major challenge."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":11118834.513341067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181039,"accession_number":"0001493152-25-008268","cik":1962011,"company_name":"Kairos Pharma, LTD.","ticker":"KAPA","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kairos Pharma presents preclinical data for KROS 101 and KROS 401 at AACR IO","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["KROS 101 (GITR agonist) inhibited tumor growth in melanoma model and increased CD4+/CD8+ T cell proliferation.","KROS 101 prevented T cell exhaustion, a key advantage over prior GITR antibody TRX518.","KROS 401 peptide inhibitor reduced M2 macrophages and showed anti-tumor effect in glioma-bearing mice.","Data presented at AACR Immuno-Oncology conference in Los Angeles, February 23-26, 2025.","CEO highlighted potential of KROS platform to address T cell exhaustion and reprogram tumor microenvironment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":11118834.513341067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181038,"accession_number":"0001493152-25-005100","cik":1962011,"company_name":"Kairos Pharma, LTD.","ticker":"KAPA","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kairos Pharma presents preclinical data on KROS 101 at AACR-JCA; shows tumor reduction in melanoma models","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KROS 101, a GITR agonist, enhanced T cell infiltration and proliferation in mouse melanoma models and human glioblastoma in vitro.","In a preclinical study, KROS 101 reduced melanoma tumor in human GITR knock-in mouse model vs. the GITR antibody TRX518.","Data presented at the 13th AACR-JCA Joint Conference from Feb 1-5, 2025 in Maui, Hawaii.","CEO Dr. John S. Yu and VP R&D Dr. Ramachandran Murali co-presented; potential for melanoma and glioblastoma therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":11118834.513341067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181037,"accession_number":"0001493152-25-002832","cik":1962011,"company_name":"Kairos Pharma, LTD.","ticker":"KAPA","form_type":"8-K","filed_at":"2025-01-17T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Kairos Pharma closes $3.5M PIPE offering of pre-funded units and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 2,500,000 Pre-Funded Units at $1.399/unit, raising gross proceeds of $3,497,500.","Each Pre-Funded Unit includes a pre-funded warrant (exercise $0.001) and 1.5 common warrants (exercise $1.40).","Amended agreement requires shareholder approval before issuing >19.99% of common stock.","Placement agents Boustead and D. Boral receive 8% cash commission plus warrants for 175,000 shares at $1.40.","Offering closed on January 16, 2025; securities sold under Section 4(a)(2) and Rule 506(b)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11118834.513341067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181036,"accession_number":"0001493152-25-002048","cik":1962011,"company_name":"Kairos Pharma, LTD.","ticker":"KAPA","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Kairos Pharma raises $3.5M in PIPE offering at $1.40/unit with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raises $3.5M gross from sale of units at $1.40/Common Unit and $1.399/Pre-Funded Unit.","Each Common Unit includes 1 share and 1.5 Common Warrants exercisable at $1.40 for 5.5 years.","Insiders enter 90-day lock-up; registration rights for resale of shares and warrant shares.","Closing expected January 15, 2025; D. Boral Capital and Boustead Securities as co-placement agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11118834.513341067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197921,"accession_number":"0001493152-24-049994","cik":1962011,"company_name":"Kairos Pharma, LTD.","ticker":"KAPA","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Kairos Pharma appoints Rahul Singhvi as director, replacing Rosemary Mazanet","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Rosemary Mazanet resigned from board effective upon appointment of new independent director; not due to disagreement.","Dr. Rahul Singhvi appointed director effective Dec 10, 2024; will serve on audit committee, chair compensation and nominating/corporate governance committees.","Singhvi is cofounder of Resilience, former CEO of Novavax (NVAX), former COO of Takeda's Vaccine business.","Singhvi receives $50K annual cash fee and $50K in RSUs vesting over three years under 2023 Equity Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":11118834.513341067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197920,"accession_number":"0001493152-24-046707","cik":1962011,"company_name":"Kairos Pharma, LTD.","ticker":"KAPA","form_type":"8-K","filed_at":"2024-11-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kairos Pharma approved for dual listing on Upstream; trading starts Nov 26","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved to dual list shares on Upstream, a MERJ Exchange market and global trading app.","Trading begins November 26, 2024 at 10:00 a.m. ET under ticker 'KAPA'.","Dual listing aims to access global investor base outside U.S., unlock liquidity, enhance price discovery.","CEO John Yu says listing supports shareholder value and advancement of lead drug ENV105 in cancer trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":11118834.513341067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197919,"accession_number":"0001493152-24-040780","cik":1962011,"company_name":"Kairos Pharma, LTD.","ticker":"KAPA","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kairos Pharma CEO to speak at Maxim Healthcare Virtual Summit; investor deck updated","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["CEO Dr. John S. Yu will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit (Oct 15-17).","Company posted an updated corporate presentation on its website at www.kairospharma.com.","No financial results or material operational updates were disclosed in the filing or attached deck."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":11118834.513341067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197918,"accession_number":"0001493152-24-039586","cik":1962011,"company_name":"Kairos Pharma, LTD.","ticker":"KAPA","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Kairos Pharma enters consulting pact with Cross Current for $700K total compensation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Consulting agreement for $200,000 cash and restricted shares valued at $500,000, subject to a six-month true-up to maintain $500K value.","Shares cannot exceed 9.99% of outstanding common stock; vest after six months with possible additional 'true up' shares.","Services include investor marketing, M&A canvassing, capital markets advisory; term is 24 months starting from NYSE American listing.","Compensation and agreement effective upon listing (Start Date); registration statement on Form S-8 planned within 30 days after listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":11118834.513341067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214087,"accession_number":"0001493152-24-038590","cik":1962011,"company_name":"Kairos Pharma, LTD.","ticker":"KAPA","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Kairos Pharma enters two service agreements: $615K cash + 50K RSUs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO.CA Technologies to provide advertising and consulting for $250,000 over 12 months.","Belair Capital Advisors to provide strategic advisory for $365,000 plus 50,000 RSUs vesting in 6 months.","Services include digital marketing, market research, business development assistance, and stakeholder communication.","Both agreements are governed by Ontario law and contain standard indemnification clauses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":11118834.513341067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214086,"accession_number":"0001493152-24-037958","cik":1962011,"company_name":"Kairos Pharma, LTD.","ticker":"KAPA","form_type":"8-K","filed_at":"2024-09-24T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Kairos Pharma enters $900K biomarker agreement with PreCheck for ENV105 trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with PreCheck Health Services for biomarker screening in ongoing lung (NCT05401110) and prostate (NCT05534646) cancer trials.","Kairos to pay $900,000 for PreCheck's lab services using SolidTumorCheck+ platform.","PreCheck will develop a companion diagnostic (three-gene PCR) for ENV105 to identify responsive patients.","Target indications: EGFR-driven lung cancer resistant to osimertinib and castrate-resistant prostate cancer.","Companion diagnostic to be submitted for FDA approval to guide Phase 3 patient selection."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11118834.513341067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214085,"accession_number":"0001493152-24-036855","cik":1962011,"company_name":"Kairos Pharma, LTD.","ticker":"KAPA","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Kairos Pharma closes $6.2M IPO; shares trade on NYSE American under KAPA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed IPO of 1,550,000 shares at $4.00/share; gross proceeds $6,200,000.","Underwriters granted 45-day option for additional 232,500 shares at same price.","Proceeds to fund Phase 1 lung cancer and Phase 2 prostate cancer trials for lead candidate ENV 105.","Issued two warrants to underwriters for 54,250 shares each at $4.80 exercise price, exercisable from Mar 2025 to Sep 2029.","Common stock began trading on NYSE American on Sept 16, 2024 under symbol KAPA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":11118834.513341067,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}